Executive readout · one minute
What the filings say
- 8-K earnings release · filed Nov 10, 2026
- Corbus Pharmaceuticals Holdings, Inc. reported a net loss of approximately $37.8 million for Q3 2026 and held $115.3 million in cash, cash equivalents, and investments, expected to fund operations into 2028. CRB-913 achieved 5% mean weight loss after 12 weeks.
- 10-Q report · filed Nov 10, 2026
- Corbus Pharmaceuticals Holdings reported that CRB-913’s 60 mg dose achieved mean 5% weight loss at 12 weeks. Nine-month 2026 net loss widened to $95.8 million from $58.0 million, with $115.3 million in cash at September 30, 2026.
The audio replay and transcript follow the call.